Group 1: Core Insights - Xinda Biopharma announced a global strategic collaboration with Takeda Pharmaceutical, with a total deal value of up to $11.4 billion, including an upfront payment of $1.2 billion [1][3][4] - The collaboration aims to accelerate the global development and commercialization of Xinda's next-generation immuno-oncology and antibody-drug conjugate therapies, covering three products: IBI363, IBI343, and IBI3001 [3][4] - Xinda will receive a total of up to $10.2 billion in potential development and sales milestone payments, in addition to sales revenue sharing for the candidates outside Greater China [3][4] Group 2: Market Impact - Following the announcement, the innovative drug ETF (589720) surged, reflecting a 20% increase in a single day, indicating strong market sentiment towards the collaboration [1][6] - The innovative drug sector has seen significant growth, with contract values exceeding $100 billion in the first nine months of the year, marking a 170% year-on-year increase [5] - The sector is expected to continue benefiting from favorable macroeconomic conditions, including potential interest rate cuts, which are seen as supportive for innovation-driven companies [5][7] Group 3: Future Outlook - The innovative drug industry is poised for substantial growth driven by international expansion, policy support, and the strengthening of R&D capabilities among Chinese companies [7] - Investors are encouraged to focus on the innovative drug ETF (589720), which tracks a representative index of high-growth biotech companies, as it has outperformed the Hang Seng Hong Kong Stock Connect Innovative Drug Index since the "924 market" [6][7] - The upcoming ESMO conference is expected to showcase a significant number of Chinese research projects, further highlighting the robust development of the innovative drug sector [5][7]
信达生物达成百亿美元合作，20cm标的科创创新药 ETF（589720）盘中领涨